Navigation Links
Hanger Orthopedic Group, Inc. Receives Positive Outlook from Standard & Poor's Rating Services
Date:7/2/2008

Inc. or the WalkAide, visit http://www.ininc.us. For more information on Hanger, visit http://www.hanger.com.


'/>"/>
SOURCE Hanger Orthopedic Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007
2. Infor-Med, Inc. Announces New Praxis EMR Version 4 with The Praxis Knowledge Exchanger(R)
3. Hanger Orthopedic Group, Inc. Announces Three Acquisitions Totaling Over $3.5 Million of Annual Net Revenue
4. Hanger Orthopedic Group, Inc. Announces 2007 Year-End Earnings Release Conference Call
5. Hanger Orthopedic Group, Inc. Announces Senior Leadership Succession Plan and Reaffirms Guidance
6. Hanger Orthopedic Group, Inc. Announces an 11% Sales Increase and a 35% Increase in EPS to $0.23 for the Quarter Ended December 31, 2007, Compared to $0.17 in the Prior Year
7. Hanger Orthopedic Group, Inc. Announces Second Quarter 2008 Earnings Release Conference Call
8. Orthopedic Development Corporations TruFUSE(R) Procedure Tops 1,750 Patients in First Year
9. QED International Associates Announces Changes to the HealthShares(TM) Composite, HealthShares(TM) Cardio Devices, and the HealthShares(TM) Orthopedic Repair Indexes
10. QED International Announces Changes to the HealthShares(TM) Orthopedic Repair Index
11. Orthopedic Surgeon Contributes Knowledge on Research and Treatment in Weekly Blogs on MyOsteoarthritisCentral.com
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Dynatronics Receives 180-Day NASDAQ Extension 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3American Association of Oral and Maxillofacial Surgeons Says Only Trained Dental and Medical Practitioners Should Administer and Monitor Anesthesia 53644 1American Association of Oral and Maxillofacial Surgeons Says Only Trained Dental and Medical Practitioners Should Administer and Monitor Anesthesia 53644 2Pennsylvania Department of Aging Seeks Consumer Input on New Health Care Option 53640 1Pennsylvania Department of Aging Seeks Consumer Input on New Health Care Option 53640 2PEAK Surgical Introduces PEAK PlasmaBlade 28TM 29 TnA 53636 1PEAK Surgical Introduces PEAK PlasmaBlade 28TM 29 TnA 53636 2PEAK Surgical Introduces PEAK PlasmaBlade 28TM 29 TnA 53636 3